Your browser doesn't support javascript.
loading
Statin Use at the Time of Initiation of Androgen Deprivation Therapy and Time to Progression in Patients With Hormone-Sensitive Prostate Cancer.
Harshman, Lauren C; Wang, Xiaodong; Nakabayashi, Mari; Xie, Wanling; Valenca, Loana; Werner, Lillian; Yu, Yongjiang; Kantoff, Aaron M; Sweeney, Christopher J; Mucci, Lorelei A; Pomerantz, Mark; Lee, Gwo-Shu Mary; Kantoff, Philip W.
Affiliation
  • Harshman LC; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Wang X; Gelb Center for Translational Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Nakabayashi M; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Xie W; Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Valenca L; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Werner L; Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Yu Y; Gelb Center for Translational Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts4Department of Urology, Shanghai Jiao Tong University School of Medicine, Xinhua Hospital, Shanghai, China.
  • Kantoff AM; Apple Tree Partners, New York, New York.
  • Sweeney CJ; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Mucci LA; Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts.
  • Pomerantz M; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Lee GS; Gelb Center for Translational Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Kantoff PW; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts2Gelb Center for Translational Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
JAMA Oncol ; 1(4): 495-504, 2015 Jul.
Article in En | MEDLINE | ID: mdl-26181260
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Prostatic Neoplasms / Antineoplastic Agents, Hormonal / Hydroxymethylglutaryl-CoA Reductase Inhibitors / Androgen Antagonists / Neoplasms, Hormone-Dependent Type of study: Diagnostic_studies / Etiology_studies / Observational_studies / Prognostic_studies Language: En Journal: JAMA Oncol Year: 2015 Type: Article
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Prostatic Neoplasms / Antineoplastic Agents, Hormonal / Hydroxymethylglutaryl-CoA Reductase Inhibitors / Androgen Antagonists / Neoplasms, Hormone-Dependent Type of study: Diagnostic_studies / Etiology_studies / Observational_studies / Prognostic_studies Language: En Journal: JAMA Oncol Year: 2015 Type: Article